{"created":"2023-06-20T16:41:23.380352+00:00","id":11879,"links":{},"metadata":{"_buckets":{"deposit":"87155f84-238f-4fd4-ad27-59f2e69ace2f"},"_deposit":{"created_by":3,"id":"11879","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"11879"},"status":"published"},"_oai":{"id":"oai:kindai.repo.nii.ac.jp:00011879","sets":["14:923:1081:1115","21:3039:3638:3646"]},"author_link":["22670"],"item_2_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2010-03-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"346","bibliographicPageStart":"333","bibliographicVolumeNumber":"56","bibliographic_titles":[{"bibliographic_title":"商経学叢"},{"bibliographic_title":"Shokei-gakuso: Journal of Business Studies","bibliographic_titleLang":"en"}]}]},"item_2_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"【概要】製薬企業においてはブロック・バスターと呼ばれる売上高の大きな新薬が競争優位の源泉であると認識されている。このブロック・バスターを生み出す研究開発プロセスでは, 研究と開発のそれぞれのプロセスにおいて, その質的特徴が大きく異なる。具体的には, 研究プロセスでは, 研究開発投資の規模の不経済が見られる一方, 開発プロセスでは, 研究開発投資の規模に比例して成果が得られるのである。そのため, 大手製薬企業は, 企業規模の拡大とともに生産性が低下する研究プロセスの成果を得るために, M&Aを研究開発の深い部分へと深化せざるを得ないのである。\n【Abstract】 Blockbusters have become internal resource of pharmaceutical companies for competitive advantage. Blockbusters R & D is divide into the research and the development processes, and the development process is much more affected by the investment scale than the research process is. Therefore, M & A by large pharmaceutical companies is deepening in the deep portion of R & D process.","subitem_description_type":"Abstract"}]},"item_2_publisher_14":{"attribute_name":"出版者 名前","attribute_value_mlt":[{"subitem_publisher":"近畿大学商経学会"}]},"item_2_source_id_22":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"04502825","subitem_source_identifier_type":"ISSN"}]},"item_2_text_7":{"attribute_name":"著者(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Miyashige, Tetsuya"}]},"item_2_text_8":{"attribute_name":"著者 所属","attribute_value_mlt":[{"subitem_text_value":"富山高等専門学校国際ビジネス学科; 専任講師"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"宮重, 徹也"},{"creatorName":"ミヤシゲ, テツヤ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"製薬企業","subitem_subject_scheme":"Other"},{"subitem_subject":"M&A","subitem_subject_scheme":"Other"},{"subitem_subject":"研究開発の特徴","subitem_subject_scheme":"Other"},{"subitem_subject":"深化","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"日本の大手製薬企業におけるM&Aの深化―競争優位の確立に向けて―","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"日本の大手製薬企業におけるM&Aの深化―競争優位の確立に向けて―"},{"subitem_title":"The deepening of M&A in Japanese Pharmaceutical Companies: To get Competitive Advantage","subitem_title_language":"en"}]},"item_type_id":"2","owner":"3","path":["1115","3646"],"pubdate":{"attribute_name":"公開日","attribute_value":"2013-07-29"},"publish_date":"2013-07-29","publish_status":"0","recid":"11879","relation_version_is_last":true,"title":["日本の大手製薬企業におけるM&Aの深化―競争優位の確立に向けて―"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-06-20T20:19:32.181819+00:00"}